Coreline Soft, a company specializing in medical artificial intelligence (AI) solutions, said on Friday that it has received preliminary listing approval from the Korea Exchange (KRX).

The company plans to debut on the tech-heavy Kosdaq market in the second half of this year, through Shinhan No. 7 Pack and the Special Purpose Acquisition Company (SPAC) dissolution and merger method.

Starting with the approval of the preliminary listing review, the company plans to proceed with the listing of the SPAC merger by preparing various matters and submitting a securities report.

Coreline Soft specializes in computer tomography (CT) image analysis and has global top-tier products and technologies. It differentiates itself from other AI medical image analysis solution companies by offering solutions based on 3D-medical imaging rather than 2D.

In particular, it has developed and secured screening solutions such as AVIEW LCS, AVIEW CAC, and AVIEW COPD for all three smoking-related diseases including lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular disease.

As Coreline Soft aims to establish itself as a global leader in diagnosing lung diseases, it has won bids for the National Cancer Center’s (NCC) lung cancer screening project alongside other lung cancer screening projects in Germany, the European Union (EU), and Italy.

Currently, the company is focusing its R&D efforts on expanding its portfolio to include interstitial lung abnormalities, aortic aneurysm analysis, bone density assessment, fatty liver, and pulmonary embolism to simultaneously screen for abnormalities that can be detected in low-dose chest CT.

"We have advanced technology and professional competitiveness in the global AI medical and healthcare market centered on chest diagnostics," said Coreline Soft CEO Kim Jin-kook. "Through the listing, we hope to expand our global market dominance to consolidate our position as a leading company in the industry."